Gujarat Themis Biosyn Limited

Gujarat Themis Biosyn Limited

Gujarat Themis Biosyn Limited has informed the Exchange about the closure of QIP Issue, with the Fund-Raising Committee approving and declaring the closure of issue period for the QIP at Rs. 354 per Equity Share, including a premium of Rs. 353 per Equity Share.

Gujarat Themis Biosyn Limited

Gujarat Themis Biosyn Limited has informed the Exchange about General Updates - Outcome of Board meeting relating to QIP Issue. The company has approved the preliminary placement document, authorized the opening of the proposed Issue of Equity Shares to eligible QIBs, and approved the floor price for the QIP.

Gujarat Themis Biosyn Limited

Gujarat Themis Biosyn Limited has informed the Exchange about General Updates, specifically the audited financial statements for the Financial Year ended March 31, 2026, along with the audit reports issued thereon by the Statutory Auditor.

Gujarat Themis Biosyn Limited

Gujarat Themis Biosyn Limited has informed the Exchange regarding the Amendment to AOA/MOA of the company, where shareholders approved changes to the Articles of Association, specifically deleting a clause related to share price determination by a registered valuer.

Gujarat Themis Biosyn Limited

Gujarat Themis Biosyn Limited has informed the Exchange regarding the Amendment to AOA/MOA of the company, where the shareholders approved the deletion of certain words from Article 13(1) Clause (c) of the Articles of Association.

Gujarat Themis Biosyn Limited

Gujarat Themis Biosyn Limited has informed the Exchange regarding Proceedings of Postal Ballot. The company has submitted the Exchange a copy of Srutinizers report along with voting results for three special resolutions: raising funds by issue of Equity Shares through Qualified Institutions Placement, amendment to the Articles of Association of the Company, and private placement of NCDs and/or Debt securities. All three resolutions were passed with requisite majority.

Gujarat Themis Biosyn Limited

Gujarat Themis Biosyn Limited held an Extraordinary General Meeting (EGM) on August 22, 2026, where resolutions related to material related party transactions, amendment to the Articles of Association, and private placement of NCDs and/or debt securities were passed with the requisite majority.

Gujarat Themis Biosyn Limited

Gujarat Themis Biosyn Limited has informed the Exchange about the transcript of the Q1 FY27 Earnings Conference Call held on August 10, 2026, and provided an update on the company's financial performance and business strategy.

Gujarat Themis Biosyn Limited

Gujarat Themis Biosyn Limited has informed the Exchange about the link to the recording of the investor/analyst conference call held on August 10, 2026.

Gujarat Themis Biosyn Limited

Gujarat Themis Biosyn Limited has informed the Exchange about Copy of Newspaper Publication regarding un-audited financial results for the quarter ended 30th June, 2026.

Gujarat Themis Biosyn Limited

Gujarat Themis Biosyn Limited has released its Q1 FY2026-27 investor presentation, highlighting a strong start to the new financial year with healthy sales volumes, improved margins, and significant strides in inorganic expansion initiatives, including the acquisition of Sanofi's brands and MicroBiopharm in Japan.

Gujarat Themis Biosyn Limited

Gujarat Themis Biosyn Limited has submitted its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, with the company's board of directors approving the results at a meeting held on August 7, 2026.

Gujarat Themis Biosyn Limited

Gujarat Themis Biosyn Limited has informed the Exchange about Schedule of meet to discuss the 1QFY27 Financial performance on Monday, 14:30 Hrs IST. The conference call will be held virtually and is open to all institutional investors and analysts.

Gujarat Themis Biosyn Limited

Gujarat Themis Biosyn Limited's promoter, Sachin D. Patel, has disclosed an inter-se transfer of shares under SEBI Takeover Regulations. The transfer involves 5,23,560 equity shares acquired by Patel from Pharmaceutical Business Group India Limited.

Gujarat Themis Biosyn Limited

Gujarat Themis Biosyn Limited has published a newspaper advertisement regarding a Notice of Extra-Ordinary General Meeting (EGM) in compliance with SEBI regulations.

Gujarat Themis Biosyn Limited

Gujarat Themis Biosyn Limited has called an Extraordinary General Meeting (EGM) on August 22, 2026, to consider approval of material related party transactions with promoter/promoter group entities and amendment to the Articles of Association of the Company.

Gujarat Themis Biosyn Limited

CTL Trusteeship Limited has submitted a disclosure under SEBI Takeover Regulations regarding the creation of indirect encumbrance by Vividhmargi Investments Private Limited over shares of Gujarat Themis Biosyn Limited, resulting in a 47.02% stake in the company.

Gujarat Themis Biosyn Limited

Gujarat Themis Biosyn Limited has informed the Exchange about a copy of newspaper publication for a postal ballot. The company has published the notice of postal ballot in the 'Western Times' (English) and 'Western Times' (Gujarati) editions on July 24, 2026.

Gujarat Themis Biosyn Limited

Gujarat Themis Biosyn Limited has informed the Exchange regarding Notice of Postal Ballot dated 22.07.2026, seeking approval of the Members of the Company on the Resolution forming part of the Notice.

Gujarat Themis Biosyn Limited

Gujarat Themis Biosyn Limited has informed the Exchange about Credit Rating- Revision. The rating assigned to the Company is CARE BBB (RWN) for long-term bank facilities and CARE A3+ (RWN) for short-term bank facilities, both placed on 'Rating Watch with Negative Implications'. The rating watch reflects concerns surrounding the company's proposed large-scale acquisitions and uncertainty regarding the funding structure for these transactions.